Advances in targeted and immune therapies for hepatocellular carcinoma.
10.3760/cma.j.cn501113-20220624-00344
- Author:
Yue Min NAN
1
;
Tong Guo MIAO
1
Author Information
1. Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Sorafenib/therapeutic use*;
Liver Neoplasms/pathology*;
Immune Checkpoint Inhibitors/therapeutic use*;
Bevacizumab/therapeutic use*;
Biosimilar Pharmaceuticals/therapeutic use*
- From:
Chinese Journal of Hepatology
2022;30(9):905-911
- CountryChina
- Language:Chinese
-
Abstract:
Targeted and immunotherapy drugs for hepatocellular carcinoma (HCC) have been rapidly developed. Atezolizumab in combination with bevacizumab has been recommended as the first-line standard of care for unresectable or advanced HCC in several national and international guidelines. The combination therapies with sindilizumab and bevacizumab biosimilar, apatinib and carrilizumab, dulvalizumab and tremelimumab are also recommended as first-line standard regimens for advanced HCC in the guideline of Chinese Society of Clinical Oncology. Local therapy combined with targeted drugs (such as sorafenib and lenvatinib) or immune checkpoint inhibitors can significantly improve outcomes. Therefore, some progress has also been made in the study of single-agent or combination regimens as perioperative neoadjuvant therapy.
